



MEETING ABSTRACT

Open Access

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?

T Byrski^{1*}, T Huzarski¹, E Marczyk¹, P Blecharz², J Gronwald¹, O Ashuryk¹, C Cybulski¹, T Dębniak¹, D Zuziak³, D Godlewski⁴, J Kladny¹, J Lubinski¹, SA Narod⁵

From Annual Conference on Hereditary Cancers 2010
Szczecin, Poland. 10-11 December 2010

Purpose

To identify host and tumor factors which predict a complete pathologic response (pCR) after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation.

Patients and methods

50 women with breast cancer and a BRCA1 mutation, who presented with stage I to III breast cancer between December 2006 and April 2010 were enrolled and treated with cisplatin 75 mg/m² every three weeks for four cycles, followed by mastectomy and conventional chemotherapy. Eight patients had prior chemotherapy for a previous cancer diagnosis. Three patients received prior chemotherapy for their current cancer diagnosis but received protocol therapy and thus were followed for toxicity and evaluated for response. Information was collected on clinical stage, grade, hormone receptor status and Her2neu (HER2) status prior to treatment. Pathologic complete response was determined by review of surgical specimens.

Results

47 patients were enrolled in the study, including 39 patients for whom this was the first primary breast cancer and who had no previous chemotherapy and 8 patients who had previously received chemotherapy. A pathologic complete response (pCR) was observed in 34 patients (68%) including 82% of women who had no previous chemotherapy and 18% of women who had previously received chemotherapy.

Conclusions

Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancer, but may be less effective in women who have been previously been treated with another form of chemotherapy.

Author details

¹Pomeranian Medical University, Szczecin, Poland. ²Oncology Institute, Kraków, Poland. ³Regional Oncology Center, Bielsko-Biala, Poland. ⁴Center for Epidemiology and Prevention, Poznań, Poland. ⁵Women's College Research Institute, Toronto, Ontario, Canada.

Published: 12 January 2012

doi:10.1186/1897-4287-10-S1-A4

Cite this article as: Byrski et al.: Why choose the treatment with cisplatin for BRCA1 breast cancers patients? *Hereditary Cancer in Clinical Practice* 2012 **10**(Suppl 1):A4.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: tomekbyr@poczta.onet.pl

¹Pomeranian Medical University, Szczecin, Poland

Full list of author information is available at the end of the article